Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(4.81)
# 76
Out of 5,165 analysts
24
Total ratings
68%
Success rate
58.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRSN NeuroSense Therapeutics | Initiates: Buy | $3 | $0.81 | +269.82% | 1 | Mar 10, 2026 | |
| OVID Ovid Therapeutics | Initiates: Buy | $3 | $1.95 | +53.85% | 1 | Dec 11, 2025 | |
| CING Cingulate | Maintains: Buy | $17 → $16 | $10.72 | +49.25% | 4 | Nov 19, 2025 | |
| PYPD PolyPid | Maintains: Buy | $10 → $9 | $4.40 | +104.55% | 3 | Nov 13, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $12 → $13 | $30.56 | -57.46% | 3 | Nov 12, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $140 → $60 | $2.57 | +2,234.63% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.89 | +237.95% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $2.52 | +138.10% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $4.31 | +271.23% | 4 | Aug 12, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $12.74 | +127.63% | 1 | Dec 5, 2024 |
NeuroSense Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $3
Current: $0.81
Upside: +269.82%
Ovid Therapeutics
Dec 11, 2025
Initiates: Buy
Price Target: $3
Current: $1.95
Upside: +53.85%
Cingulate
Nov 19, 2025
Maintains: Buy
Price Target: $17 → $16
Current: $10.72
Upside: +49.25%
PolyPid
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.40
Upside: +104.55%
Capricor Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $30.56
Upside: -57.46%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $140 → $60
Current: $2.57
Upside: +2,234.63%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.89
Upside: +237.95%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.52
Upside: +138.10%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $4.31
Upside: +271.23%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $12.74
Upside: +127.63%